MDT Medtronic
Health Care · Health Care Equipment · close $94.75 (2026-10-16) · latest quarter in EDGAR: 2026-07-31
Medtronic (MDT) has a ThetaGrade House Rating of 58/100 (grade C), ranking #13 of 150 in Health Care. Its strongest pillars are analyst sentiment (83) and valuation (69); its weakest is balance sheet (49). TTM revenue growth is 9.8% and operating margin 18.1%.
Data as of .
Analyst sentiment
weight 7.5% · 83| Consensus score (1–5) (3.8%) | derived | 49 |
| 90-day net rating shift (3.8%) | derived | 90 |
Growth
weight 30.83% · 54| Revenue growth YoY (TTM) (12.3%) | 9.8% | 48 |
| EPS growth YoY (TTM) (12.3%) | 12.2% | 48 |
| Revenue acceleration (6.2%) | 3.9% | 77 |
Profitability
weight 18.5% · 51| Operating margin (9.9%) | 18.1% | 65 |
| 4Q gross-margin change (8.6%) | -0.3% | 36 |
Balance sheet
weight 18.5% · 49| Net debt / EBITDA (9.9%) | 2.10× | 43 |
| Current ratio (4.9%) | 2.07 | 44 |
| Interest coverage (3.7%) | 9.49× | 70 |
Cash flow
weight 12.33% · 65| FCF margin (6.2%) | 14.9% | 60 |
| FCF yield (6.2%) | 4.5% | 69 |
Valuation
weight 12.33% · 69| P/E (inverted) (6.2%) | 23.34× | 74 |
| EV/Sales (inverted) (6.2%) | 3.77× | 63 |
Technicals (EOD)
| RSI(14) | 64.1 |
| EMA 9 / 21 | 92.06 / 90.72 · crossed up 4d ago |
| 200-day SMA | 88.30 |
| Volume vs 20d avg | 0.91× |
| 20-day return | 2.1% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like MDT's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is MDT's House Rating?
- MDT scores 58 out of 100 (grade C) as of 2026-10-16, ranking #13 of 150 Health Care stocks we cover.
- What do analysts say about MDT?
- ThetaGrade's analyst-sentiment pillar for MDT scores 83/100 against its sector peers, which we read as positive. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does MDT report earnings next?
- We do not have a reliable estimate for MDT's next earnings date (irregular SEC filing history); a rough window is 2026-11-03 to 2026-12-01. Check the company's investor-relations page.
- Is MDT a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology